Aligos Therapeutics Reports Positive 96-Week Data for Pevifoscorvir Sodium in Chronic Hepatitis B

Reuters11-10
Aligos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive 96-Week Data for Pevifoscorvir Sodium in Chronic Hepatitis B

Aligos Therapeutics Inc. announced positive data from multiple presentations at the American Association for the Study of Liver Disease's The Liver Meeting® 2025, held November 7-11, 2025, in Washington, D.C. The company highlighted clinical results for pevifoscorvir sodium, a capsid assembly modulator under investigation for the treatment of chronic hepatitis B virus (HBV) infection. An oral presentation and several posters detailed 96-week treatment and post-treatment data, suggesting pevifoscorvir sodium demonstrates potent suppression of HBV DNA and sustained reduction of HBV antigen levels in treatment-naive or currently-not-treated subjects. The results were presented by Professor Man-Fung Yuen of the University of Hong Kong. Aligos also presented preclinical data on other investigational agents, including the capsid assembly modulator ALG-001075, which prevents cccDNA formation and HBV DNA integration in vitro. The company indicated ongoing progress in its HBV antisense oligonucleotide $(ASO)$ program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aligos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571440-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment